Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hallucinogens and Psychedelics

Hallucinogens and Psychedelics

Hallucinogens are psychoactive substances that profoundly alter perceptual experiences, generating unreal visual and sensory images. Often referred to as psychedelic drugs — a term derived from the Greek words "psyche" (mind) and "delos" (revealing) — these substances include marijuana and lysergic acid diethylamide (LSD), among others. These drugs vary in intensity and effects.
Marijuana, derived from the dried leaves and flowers of the hemp plant, contains...

CNS Stimulants: Psychedelic Agents

CNS Stimulants: Psychedelic Agents

Hallucinogens, also known as psychedelic drugs, are a class of substances known for their ability to alter perception, cognition, and emotions. Despite their profound effects on the mind, these drugs are non-addictive, setting them apart from many other abused substances. The mechanism of action of these drugs lies in their impact on the 5-HT2A receptor in the brain. Upon activation, this receptor couples to Gq-type G proteins, triggering a cascade that releases intracellular calcium. This...

Psychosurgery

Psychosurgery

Psychosurgery, the surgical alteration or permanent removal of brain tissue to alleviate severe psychological conditions, stands as one of the most radical and controversial treatments in the history of mental health care. Its development and application have evolved significantly, marked by dramatic shifts in scientific understanding and ethical perspectives.
Historical Development of Psychosurgery
In the 1930s, Portuguese neurologist Antonio Egas Moniz introduced a surgical procedure designed...

Altered States of Awareness

Altered States of Awareness

Altered states of consciousness represent significant deviations from one's normal mental state. These deviations can range from subtle changes in awareness to profound transformations in perception, thought processes, and sensory experiences. Altered states of consciousness can be triggered by various factors, including drug use, meditation, hypnosis, illness, or even intense fatigue.
The ingestion of substances like stimulants or hallucinogens leads to chemical alterations in the brain...

Psychosis: Goals of Pharmacotherapy

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.

Preclinical Development: Overview

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Linking human brain functional connectivity to underlying neurotransmission.

bioRxiv : the preprint server for biology·2026

Same author

General Anesthesia and Discrete Components of Ketamine Neurophysiology.

JAMA psychiatry·2026

Same author

Digital Twin Brain simulation and manipulation of a functional brain network underlying mental illness.

bioRxiv : the preprint server for biology·2026

Same author

Low-dose naltrexone as an adjunctive treatment for major depressive disorder: findings from a randomized, double-blind, placebo-controlled hybrid parallel-arm study.

Frontiers in pharmacology·2026

Same author

LSD microdosing for major depressive disorder: Mood and pharmacokinetic outcomes from a Phase 2a trial.

Progress in neuro-psychopharmacology & biological psychiatry·2026

Same author

What is it like to microdose LSD for depression? a thematic analysis of participant interviews from an open-label trial.

Therapeutic advances in psychopharmacology·2025

Search research articles

Related Experiment Video

Updated: Oct 1, 2025

The Use of Pharmacological-challenge fMRI in Pre-clinical Research: Application to the 5-HT System

The Use of Pharmacological-challenge fMRI in Pre-clinical Research: Application to the 5-HT System

Published on: April 25, 2012

The challenges ahead for psychedelic 'medicine'.

Suresh Muthukumaraswamy¹, Anna Forsyth¹, Rachael L Sumner¹

¹School of Pharmacy, The University of Auckland, Auckland, New Zealand.

The Australian and New Zealand Journal of Psychiatry

|March 4, 2022

Summary

This summary is machine-generated.

The psychedelic renaissance presents unique challenges for medical integration. This viewpoint critically examines research design, funding, and societal factors to ensure responsible implementation of psychedelic medicine.

Keywords:

Psychedelic medicine mental health research design

More Related Videos

Rapid High-throughput Species Identification of Botanical Material Using Direct Analysis in Real Time High Resolution Mass Spectrometry

Rapid High-throughput Species Identification of Botanical Material Using Direct Analysis in Real Time High Resolution Mass Spectrometry

Published on: October 2, 2016

Ole Isacson: Development of New Therapies for Parkinson's Disease

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

Related Experiment Videos

Last Updated: Oct 1, 2025

The Use of Pharmacological-challenge fMRI in Pre-clinical Research: Application to the 5-HT System

The Use of Pharmacological-challenge fMRI in Pre-clinical Research: Application to the 5-HT System

Published on: April 25, 2012

Rapid High-throughput Species Identification of Botanical Material Using Direct Analysis in Real Time High Resolution Mass Spectrometry

Rapid High-throughput Species Identification of Botanical Material Using Direct Analysis in Real Time High Resolution Mass Spectrometry

Published on: October 2, 2016

Ole Isacson: Development of New Therapies for Parkinson's Disease

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

Area of Science:

Neuroscience
Psychiatry
Pharmacology

Background:

The psychedelic renaissance signifies growing interest in psychedelics for therapeutic use.
Existing literature primarily focuses on potential benefits, with less attention to implementation challenges.
Psychedelic medicine, as a revived field, requires careful consideration of its unique obstacles.

Purpose of the Study:

To critically analyze the challenges facing the integration of psychedelic medicine into contemporary healthcare.
To identify key areas of concern in research methodology, the scientific environment, and clinical implementation.
To propose strategies for mitigating these challenges in future research protocols.

Main Methods:

A critical review and discussion of existing practices in psychedelic research.
Identification and categorization of challenges across study design, research environment, and clinical implementation.
Formulation of recommendations for improving research protocols.

Main Results:

Challenges identified in research design include issues with blinding, expectancy effects, therapeutic protocols, and bias.
Broader environmental challenges encompass evidence establishment in medical science, funding landscapes, and regulatory conflicts.
Implementation hurdles involve social and economic contexts of integrating psychedelic therapies.

Conclusions:

Addressing these multifaceted challenges is crucial for the responsible advancement of psychedelic medicine.
Suggestions are provided to enhance current research protocols and facilitate successful clinical integration.
A proactive and critical approach is necessary to navigate the complexities of psychedelic therapy research and application.